Chapter 03: A Review of MD Anderson Research in the Early Seventies and a Discussion of Clinical Trials

Dr. Bast begins this chapter by noting that, in the mid-seventies he wrote a review of research on BCG and cancer for the New England Journal of Medicine and included comments on the poor quality of research at MD Anderson. He gives further context, noting the controversies over randomized clinical trials and the bias at MD Anderson for conducting single arm trials. Dr. Bast next explains why today studies of targeted therapy can be productively advanced by single-arm trials, though they require final confirmation by randomized trials to win FDA approval for any drugs or procedures.https://openworks.mdanderson.org/mchv_interviewchapters/1437/thumbnail.jp